Company Overview and News
The hottest commodity oil has been on a solid run this year thanks to a tightening oil market and rising global demand. Rounds of news about new supply disruption are adding strength to the oil price, making the case for energy stocks appealing. Supply Declining The looming Iran sanctions and falling Libya and Venezuela output were the biggest catalysts in driving oil price lately. The United States is expected to halt oil exports from the fifth-biggest producer Iran by November though some waivers can be granted while production in Libya has halved in five months to 527,000 barrels per day.
APC IMO HFC MUR.WI MUR OXY IMO AEUA
CALGARY, July 10 (Reuters) - Executives at Canada's largest integrated oil and gas producers on Tuesday downplayed the severity of transportation bottlenecks to move oil in the near term, citing existing pipeline commitments and refining capabilities.
HSE ENB ENBBF CVE IMO CVE EBBNF ENB HUSKF IMO SU SU
Executives from the biggest oilsands companies in Canada say concerns about getting their products to market are starting to ease in the wake of the regulatory approval of Enbridge Inc.'s $9-billion Line 3 pipeline replacement project.
ENBBF CVE IMO ENB HUSKF IMO SU HSE ENB CNQ CVE EBBNF SU
Suncor Energy Inc. (SU - Free Report) recently announced that its Syncrude oil sands project in Alberta is likely to resume full production in September. Following a power outage in Jun 20, the Syncrude project went offline. The disruption resulted from a transformer trip that caused power loss and steam generation. While no casualty was recorded from the outage, all the process units of the facility have been shut down since then.
IMO BCEI IMO SU SU
July 9 (Reuters) - Suncor Energy Inc said on Monday its Syncrude oil sands project in Western Canada will resume some production in July, sooner than expected, and hit full capacity in September, following an outage last month that disrupted total output.
IMO XOM IMO SU SU
CALGARY (Bloomberg) -- Canadian crude supplies may remain tight in the coming weeks as Suncor Energy Inc. works to bring its massive Syncrude oil-sands operation back online, a process that the company said won’t be completed until September.
IMO IMO CEO SU SU
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
IMO IMO SU SU
(Reuters) - Suncor Energy Inc said on Monday its Syncrude oil sands project in Western Canada will resume some production in July, sooner than expected, and hit full capacity in September, following an outage last month that disrupted total output.
IMO XOM IMO SU SU
Dorian LPG Ltd. (LPG - Free Report) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for LPG broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness.
ISCA LPG ISCB IMO IMO
International Speedway (ISCA - Free Report) just came out with quarterly earnings of $0.37 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.30 per share a year ago. These figures are adjusted for non-recurring items.
ISCA FOX ISCB IMO IMO FOXA
One stock that might be an intriguing choice for investors right now is Imperial Oil Limited (IMO - Free Report) . This is because this security in the Oil and Gas - Integrated - Canadian space is seeing solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective. This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board.
IMO DB IMO DLPH
NEW YORK (Reuters) - Production at Syncrude Canada’s oil sands facility near Fort McMurray, Alberta is likely to remain offline at least through July, a Suncor Energy Inc (SU.TO) spokeswoman reaffirmed on Tuesday.
IMO IMO SU SU
8h - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
9h - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to IMO / Imperial Oil Ltd. on message board site Silicon Investor.
as of ET